Nuveen Asset Management, LLC Galectin Therapeutics Inc Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 27,623 shares of GALT stock, worth $43,920. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,623

Previous 27,623 -0.0%

Holding current value

$43,920

Previous $75,000 57.33%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$2.13 - $4.2 $58,836 - $116,016	27,623 New	27,623 $62,000
Q2 2021 Aug 16, 2021	SELL	$2.07 - $5.1 $366,462 - $902,878	-177,035 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$1.96 - $2.57 $15,319 - $20,087	-7,816 Reduced 4.23%	177,035 $384,000
Q4 2020 Feb 16, 2021	BUY	$2.24 - $2.87 $6,641 - $8,509	2,965 Added 1.63%	184,851 $414,000
Q3 2020 Nov 16, 2020	SELL	$2.53 - $3.64 $144 - $207	-57 Reduced 0.03%	181,886 $486,000
Q2 2020 Aug 14, 2020	BUY	$1.66 - $3.15 $86,188 - $163,551	51,921 Added 39.93%	181,943 $556,000
Q1 2020 May 14, 2020	BUY	$1.51 - $3.0 $34,352 - $68,250	22,750 Added 21.21%	130,022 $254,000
Q4 2019 Feb 14, 2020	SELL	$2.79 - $4.32 $41,688 - $64,549	-14,942 Reduced 12.23%	107,272 $307,000
Q3 2019 Nov 14, 2019	BUY	$3.0 - $4.05 $123,753 - $167,066	41,251 Added 50.95%	122,214 $449,000
Q2 2019 Aug 15, 2019	BUY	$3.61 - $5.0 $292,276 - $404,815	80,963 New	80,963 $336,000

Others Institutions Holding GALT

# of Institutions

112

Shares Held

9.93M

Call Options Held

3.78M

Put Options Held

5.27M

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $94.5M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Galectin Therapeutics Inc Transaction History